{"url_path":"/sec/crmd/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1410098/0001410098-26-000021-index.html","accession_number":"0001410098-26-000021","cik":"0001410098","ticker":"CRMD","issuer_name":"CorMedix Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1410098/0001410098-26-000021-index.html","primary_entity_key":"0001410098","primary_entity_name":"CorMedix Inc."},"word_count":604,"has_tables":true,"body_markdown":"crmd-20260331\n0001410098--12-312026Q1FALSExbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:EURcrmd:Segment00014100982026-01-012026-03-3100014100982026-05-1100014100982026-03-3100014100982025-12-310001410098us-gaap:ProductMember2026-01-012026-03-310001410098us-gaap:ProductMember2025-01-012025-03-310001410098crmd:ContractRevenueMember2026-01-012026-03-310001410098crmd:ContractRevenueMember2025-01-012025-03-3100014100982025-01-012025-03-310001410098us-gaap:CommonStockMember2025-12-310001410098us-gaap:PreferredStockMember2025-12-310001410098us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001410098us-gaap:AdditionalPaidInCapitalMember2025-12-310001410098us-gaap:RetainedEarningsMember2025-12-310001410098us-gaap:CommonStockMember2026-01-012026-03-310001410098us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001410098us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001410098us-gaap:RetainedEarningsMember2026-01-012026-03-310001410098us-gaap:CommonStockMember2026-03-310001410098us-gaap:PreferredStockMember2026-03-310001410098us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001410098us-gaap:AdditionalPaidInCapitalMember2026-03-310001410098us-gaap:RetainedEarningsMember2026-03-310001410098us-gaap:CommonStockMember2024-12-310001410098us-gaap:PreferredStockMember2024-12-310001410098us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001410098us-gaap:AdditionalPaidInCapitalMember2024-12-310001410098us-gaap:RetainedEarningsMember2024-12-3100014100982024-12-310001410098us-gaap:CommonStockMember2025-01-012025-03-310001410098us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001410098us-gaap:PreferredStockMember2025-01-012025-03-310001410098us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001410098us-gaap:RetainedEarningsMember2025-01-012025-03-310001410098us-gaap:CommonStockMember2025-03-310001410098us-gaap:PreferredStockMember2025-03-310001410098us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001410098us-gaap:AdditionalPaidInCapitalMember2025-03-310001410098us-gaap:RetainedEarningsMember2025-03-3100014100982025-03-310001410098crmd:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-01-012026-03-310001410098crmd:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001410098crmd:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-01-012026-03-310001410098crmd:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001410098crmd:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-01-012026-03-310001410098crmd:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-01-012025-03-310001410098crmd:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2026-01-012026-03-310001410098crmd:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001410098crmd:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2026-01-012026-03-310001410098crmd:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001410098crmd:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2026-01-012026-03-310001410098crmd:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001410098crmd:VolumeIncentiveRebateMember2026-03-310001410098crmd:VolumeIncentiveRebateMember2025-12-310001410098crmd:VolumeIncentiveRebatesMember2025-12-310001410098crmd:MedicaidAndCommercialRebatesMember2025-12-310001410098crmd:DistributionServiceFeesMember2025-12-310001410098crmd:AccruedShelfStockLiabilityMember2025-12-310001410098crmd:AccruedReturnsAllowanceMember2025-12-310001410098crmd:PromptPayAndOtherDiscountsMember2025-12-310001410098crmd:VolumeIncentiveRebatesMember2026-01-012026-03-310001410098crmd:MedicaidAndCommercialRebatesMember2026-01-012026-03-310001410098crmd:DistributionServiceFeesMember2026-01-012026-03-310001410098crmd:AccruedShelfStockLiabilityMember2026-01-012026-03-310001410098crmd:AccruedReturnsAllowanceMember2026-01-012026-03-310001410098crmd:PromptPayAndOtherDiscountsMember2026-01-012026-03-310001410098crmd:VolumeIncentiveRebatesMember2026-03-310001410098crmd:MedicaidAndCommercialRebatesMember2026-03-310001410098crmd:DistributionServiceFeesMember2026-03-310001410098crmd:AccruedShelfStockLiabilityMember2026-03-310001410098crmd:AccruedReturnsAllowanceMember2026-03-310001410098crmd:PromptPayAndOtherDiscountsMember2026-03-310001410098us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember2026-01-012026-03-310001410098us-gaap:StockOptionMember2026-01-012026-03-310001410098us-gaap:StockOptionMember2025-01-012025-03-310001410098us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001410098us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001410098us-gaap:MoneyMarketFundsMember2026-03-310001410098us-gaap:MoneyMarketFundsMember2025-12-310001410098us-gaap:CommercialPaperMember2025-12-310001410098us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001410098us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-03-310001410098us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-03-310001410098us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2026-03-310001410098crmd:MarketableEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001410098crmd:MarketableEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-03-310001410098crmd:MarketableEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-03-310001410098crmd:MarketableEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2026-03-310001410098crmd:ContingentConsiderationLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001410098crmd:ContingentConsiderationLiabilityMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-03-310001410098crmd:ContingentConsiderationLiabilityMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-03-310001410098crmd:ContingentConsiderationLiabilityMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2026-03-310001410098us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001410098us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001410098us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001410098us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001410098us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001410098us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001410098us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001410098us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001410098us-gaap:FairValueMeasurementsRecurringMember2025-12-310001410098us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001410098us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001410098us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001410098crmd:MarketableEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001410098crmd:MarketableEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001410098crmd:MarketableEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001410098crmd:MarketableEquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001410098crmd:ContingentConsiderationLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001410098crmd:ContingentConsiderationLiabilityMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001410098crmd:ContingentConsiderationLiabilityMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001410098crmd:ContingentConsiderationLiabilityMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-12-310001410098crmd:MelintaMember2025-08-292025-08-290001410098crmd:MelintaMember2025-08-290001410098crmd:MelintaMemberus-gaap:MarketingRelatedIntangibleAssetsMember2025-08-290001410098crmd:MelintaMemberus-gaap:InProcessResearchAndDevelopmentMember2025-08-290001410098crmd:MelintaMember2026-03-310001410098crmd:MelintaMembercrmd:CandidaMember2026-03-310001410098crmd:MelintaMembercrmd:AspergillusMember2026-03-310001410098crmd:MelintaMembercrmd:PneumocystisMember2026-03-310001410098crmd:MelintaMemberus-gaap:FairValueInputsLevel3Member2025-12-310001410098crmd:MelintaMemberus-gaap:FairValueInputsLevel3Member2026-01-012026-03-310001410098crmd:MelintaMemberus-gaap:FairValueInputsLevel3Member2026-03-310001410098crmd:MelintaMemberus-gaap:MeasurementInputDiscountRateMember2026-01-012026-03-310001410098us-gaap:MeasurementInputRiskFreeInterestRateMember2026-03-310001410098us-gaap:MeasurementInputRiskFreeInterestRateMember2025-08-290001410098us-gaap:MeasurementInputPriceVolatilityMember2026-03-310001410098us-gaap:MeasurementInputPriceVolatilityMember2025-08-290001410098crmd:NetSalesRezzayoProductDiscountRateMember2026-03-310001410098crmd:NetSalesRezzayoProductDiscountRateMember2025-08-290001410098crmd:NetSalesMinocinProductDiscountRateMember2026-03-310001410098crmd:NetSalesMinocinProductDiscountRateMember2025-08-290001410098crmd:EarnoutPaymentDiscountRateMember2026-03-310001410098crmd:EarnoutPaymentDiscountRateMember2025-08-290001410098crmd:REZZAYOMilestonePaymentDiscountRateMember2026-03-310001410098crmd:REZZAYOMilestonePaymentDiscountRateMember2025-08-290001410098crmd:MelintaMember2026-01-012026-03-310001410098crmd:MelintaMember2025-01-012025-03-310001410098crmd:REZZAYOLicenseAgreementMember2026-03-310001410098srt:ScenarioForecastMember2026-10-012026-12-3100014100982026-02-020001410098srt:BoardOfDirectorsChairmanMember2026-03-310001410098crmd:SeriesC3Member2026-03-310001410098crmd:SeriesC3Member2025-12-310001410098us-gaap:SeriesEPreferredStockMember2026-03-310001410098us-gaap:SeriesEPreferredStockMember2025-12-310001410098us-gaap:RestrictedStockUnitsRSUMember2026-03-310001410098us-gaap:RestrictedStockUnitsRSUMember2025-12-310001410098us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001410098us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001410098srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001410098srt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001410098us-gaap:MeasurementInputSharePriceMemberus-gaap:FairValueInputsLevel1Member2025-03-310001410098us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:FairValueInputsLevel1Member2025-03-310001410098us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:FairValueInputsLevel2Member2025-03-310001410098us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:FairValueInputsLevel3Member2025-03-310001410098crmd:RemainingTermYearsMemberus-gaap:FairValueInputsLevel1Member2025-03-310001410098crmd:RemainingTermYearsMemberus-gaap:FairValueInputsLevel2Member2025-03-310001410098crmd:RemainingTermYearsMemberus-gaap:FairValueInputsLevel3Member2025-03-310001410098us-gaap:MeasurementInputExpectedDividendRateMemberus-gaap:FairValueInputsLevel1Member2025-03-310001410098us-gaap:MeasurementInputExpectedDividendRateMemberus-gaap:FairValueInputsLevel2Member2025-03-310001410098us-gaap:MeasurementInputExpectedDividendRateMemberus-gaap:FairValueInputsLevel3Member2025-03-310001410098us-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:FairValueInputsLevel1Member2025-03-310001410098us-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:FairValueInputsLevel2Member2025-03-310001410098us-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:FairValueInputsLevel3Member2025-03-310001410098us-gaap:MeasurementInputSharePriceMemberus-gaap:FairValueInputsLevel1Member2026-03-310001410098us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:FairValueInputsLevel1Member2026-03-310001410098us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:FairValueInputsLevel2Member2026-03-310001410098us-gaap:MeasurementInputPriceVolatilityMemberus-gaap:FairValueInputsLevel3Member2026-03-310001410098crmd:RemainingTermYearsMemberus-gaap:FairValueInputsLevel1Member2026-03-310001410098crmd:RemainingTermYearsMemberus-gaap:FairValueInputsLevel2Member2026-03-310001410098crmd:RemainingTermYearsMemberus-gaap:FairValueInputsLevel3Member2026-03-310001410098us-gaap:MeasurementInputExpectedDividendRateMemberus-gaap:FairValueInputsLevel1Member2026-03-310001410098us-gaap:MeasurementInputExpectedDividendRateMemberus-gaap:FairValueInputsLevel2Member2026-03-310001410098us-gaap:MeasurementInputExpectedDividendRateMemberus-gaap:FairValueInputsLevel3Member2026-03-310001410098us-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:FairValueInputsLevel1Member2026-03-310001410098us-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:FairValueInputsLevel2Member2026-03-310001410098us-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:FairValueInputsLevel3Member2026-03-310001410098us-gaap:EmployeeStockOptionMember2026-03-310001410098crmd:PerformanceStockUnitsMember2026-01-012026-03-310001410098crmd:PerformanceStockUnitsMember2025-01-012025-03-310001410098crmd:StockOptionsMember2026-01-012026-03-310001410098crmd:StockOptionsMember2025-01-012025-03-310001410098us-gaap:CostOfSalesMember2026-01-012026-03-310001410098us-gaap:CostOfSalesMember2025-01-012025-03-310001410098us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001410098us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001410098us-gaap:SellingAndMarketingExpenseMember2026-01-012026-03-310001410098us-gaap:SellingAndMarketingExpenseMember2025-01-012025-03-310001410098us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001410098us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001410098crmd:BARDAAgreementMember2023-07-012023-07-310001410098crmd:BARDAAgreementMember2023-07-012026-03-310001410098crmd:ContractRevenueMembercrmd:BARDAAgreementMember2026-01-012026-03-310001410098crmd:EmployeeAndContractedEmployeeExpenseMember2026-01-012026-03-310001410098crmd:EmployeeAndContractedEmployeeExpenseMember2025-01-012025-03-310001410098crmd:OtherResearchAndDevelopmentMember2026-01-012026-03-310001410098crmd:OtherResearchAndDevelopmentMember2025-01-012025-03-310001410098crmd:OtherSellingAndMarketingMember2026-01-012026-03-310001410098crmd:OtherSellingAndMarketingMember2025-01-012025-03-310001410098crmd:OtherGeneralAndAdministrativeMember2026-01-012026-03-310001410098crmd:OtherGeneralAndAdministrativeMember2025-01-012025-03-310001410098crmd:DefenCathMember2026-01-012026-03-310001410098crmd:DefenCathMember2025-01-012025-03-310001410098crmd:MelintaPortfolioMember2026-01-012026-03-310001410098crmd:MelintaPortfolioMember2025-01-012025-03-31\n\n[Table of](#i0fdbfbedd57d460da77b9a8ab76925e1_7)[Contents](#i0fdbfbedd57d460da77b9a8ab76925e1_7)\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, D.C. 20549\n\nFORM 10-Q\n\n(Mark One)\n\n☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the quarterly period ended March 31, 2026\n\n☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from ________ to ________\n\nCommission file number 001-34673\n\nCORMEDIX INC.\n\n(Exact Name of Registrant as Specified in Its Charter)\n\nDelaware\n\n20-5894890\n\n(State or Other Jurisdiction of\n\n Incorporation or Organization)\n\n(I.R.S. Employer\n\n Identification No.)\n\n389 Interpace Pkwy, Suite 450, Parsippany, NJ\n\n07054\n\n(Address of Principal Executive Offices)(Zip Code)\n\n(908) 517-9500\n\n(Registrant’s Telephone Number, Including Area Code)\n\n300 Connell Drive, Suite 4200, Berkeley Heights, NJ07922\n\n(Former Address of Principal Executive Offices)\n(Zip Code)\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading Symbol(s)Name of each exchange on which registered\n\nCommon stock, $0.001 par valueCRMDNasdaq Global Market\n\nIndicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\nLarge accelerated filer ☐Accelerated filer ☐\n\nNon-accelerated filer ☒Smaller reporting company\n☐\n\nEmerging Growth Company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\nThe number of shares outstanding of the issuer’s common stock, as of May 11, 2026 was 78,451,891.\n\n[Table of](#i0fdbfbedd57d460da77b9a8ab76925e1_7)[Contents](#i0fdbfbedd57d460da77b9a8ab76925e1_7)\n\nCORMEDIX INC. AND SUBSIDIARIES\n\nINDEX\n\nPage\n\n[PART I FINANCIAL INFORMATION](#i0fdbfbedd57d460da77b9a8ab76925e1_10)\n\n[1](#i0fdbfbedd57d460da77b9a8ab76925e1_10)\n\n[Item 1.](#i0fdbfbedd57d460da77b9a8ab76925e1_13)\n\n[Unaudited Condensed Consolidated Financial Statements](#i0fdbfbedd57d460da77b9a8ab76925e1_13)\n\n[1](#i0fdbfbedd57d460da77b9a8ab76925e1_13)\n\n[Condensed](#i0fdbfbedd57d460da77b9a8ab76925e1_16)[Consolidated Balance Sheets as of](#i0fdbfbedd57d460da77b9a8ab76925e1_16)[M](#i0fdbfbedd57d460da77b9a8ab76925e1_16)[arch 31, 2026 and December 31, 2025](#i0fdbfbedd57d460da77b9a8ab76925e1_16)\n\n[2](#i0fdbfbedd57d460da77b9a8ab76925e1_16)\n\n[ Condensed Consolidated Statements of Operations and Comprehensive Income for the Three Months Ended March 31, 2026 and 2025](#i0fdbfbedd57d460da77b9a8ab76925e1_19)\n\n[3](#i0fdbfbedd57d460da77b9a8ab76925e1_19)\n\n[ ](#i0fdbfbedd57d460da77b9a8ab76925e1_22)[Condensed Consolidated](#i0fdbfbedd57d460da77b9a8ab76925e1_22)[Statements of Changes in Stockholders’ Equity for the Three](#i0fdbfbedd57d460da77b9a8ab76925e1_22)[Months Ended](#i0fdbfbedd57d460da77b9a8ab76925e1_22)[M](#i0fdbfbedd57d460da77b9a8ab76925e1_22)[arch 3](#i0fdbfbedd57d460da77b9a8ab76925e1_22)[1, 202](#i0fdbfbedd57d460da77b9a8ab76925e1_22)[6 and 2025](#i0fdbfbedd57d460da77b9a8ab76925e1_22)\n\n[4](#i0fdbfbedd57d460da77b9a8ab76925e1_22)\n\n[ ](#i0fdbfbedd57d460da77b9a8ab76925e1_25)[Condensed](#i0fdbfbedd57d460da77b9a8ab76925e1_25)[Consolidated Statements of Cash Flows for the](#i0fdbfbedd57d460da77b9a8ab76925e1_25)[Three](#i0fdbfbedd57d460da77b9a8ab76925e1_25)[Months Ended](#i0fdbfbedd57d460da77b9a8ab76925e1_25)[M](#i0fdbfbedd57d460da77b9a8ab76925e1_25)[arch 31, 202](#i0fdbfbedd57d460da77b9a8ab76925e1_25)[6 and 2025](#i0fdbfbedd57d460da77b9a8ab76925e1_25)\n\n[5](#i0fdbfbedd57d460da77b9a8ab76925e1_25)\n\n[Notes to Unaudited Condensed Consolidated Financial Statements](#i0fdbfbedd57d460da77b9a8ab76925e1_28)\n\n[6](#i0fdbfbedd57d460da77b9a8ab76925e1_28)\n\n[Item 2.](#i0fdbfbedd57d460da77b9a8ab76925e1_76)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#i0fdbfbedd57d460da77b9a8ab76925e1_76)\n\n[23](#i0fdbfbedd57d460da77b9a8ab76925e1_76)\n\n[Item 3.](#i0fdbfbedd57d460da77b9a8ab76925e1_100)\n\n[Quantitative and Qualitative Disclosure About Market Risk](#i0fdbfbedd57d460da77b9a8ab76925e1_100)\n\n[29](#i0fdbfbedd57d460da77b9a8ab76925e1_100)\n\n[Item 4.](#i0fdbfbedd57d460da77b9a8ab76925e1_103)\n\n[Controls and Procedures](#i0fdbfbedd57d460da77b9a8ab76925e1_103)\n\n[29](#i0fdbfbedd57d460da77b9a8ab76925e1_103)\n\n[PART II OTHER INFORMATION](#i0fdbfbedd57d460da77b9a8ab76925e1_106)\n\n[31](#i0fdbfbedd57d460da77b9a8ab76925e1_106)\n\n[Item 1.](#i0fdbfbedd57d460da77b9a8ab76925e1_109)\n\n[Legal Proceedings](#i0fdbfbedd57d460da77b9a8ab76925e1_109)\n\n[31](#i0fdbfbedd57d460da77b9a8ab76925e1_109)\n\n[Item 1A.](#i0fdbfbedd57d460da77b9a8ab76925e1_112)\n\n[Risk Factors](#i0fdbfbedd57d460da77b9a8ab76925e1_112)\n\n[31](#i0fdbfbedd57d460da77b9a8ab76925e1_112)\n\n[Item 2.](#i0fdbfbedd57d460da77b9a8ab76925e1_115)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds](#i0fdbfbedd57d460da77b9a8ab76925e1_115)\n\n[31](#i0fdbfbedd57d460da77b9a8ab76925e1_115)\n\n[Item 3.](#i0fdbfbedd57d460da77b9a8ab76925e1_118)\n\n[Defaults Upon Senior Securities](#i0fdbfbedd57d460da77b9a8ab76925e1_118)\n\n[31](#i0fdbfbedd57d460da77b9a8ab76925e1_118)\n\n[Item 4.](#i0fdbfbedd57d460da77b9a8ab76925e1_121)\n\n[Mine Safety Disclosure](#i0fdbfbedd57d460da77b9a8ab76925e1_121)\n\n[32](#i0fdbfbedd57d460da77b9a8ab76925e1_121)\n\n[Item 5.](#i0fdbfbedd57d460da77b9a8ab76925e1_124)\n\n[Other Information](#i0fdbfbedd57d460da77b9a8ab76925e1_124)\n\n[32](#i0fdbfbedd57d460da77b9a8ab76925e1_124)\n\n[Item 6.](#i0fdbfbedd57d460da77b9a8ab76925e1_127)\n\n[Exhibits](#i0fdbfbedd57d460da77b9a8ab76925e1_127)\n\n[33](#i0fdbfbedd57d460da77b9a8ab76925e1_127)\n\n[SIGNATURES](#i0fdbfbedd57d460da77b9a8ab76925e1_130)\n\n[34](#i0fdbfbedd57d460da77b9a8ab76925e1_130)\n\ni\n\n[Table of](#i0fdbfbedd57d460da77b9a8ab76925e1_7)[Contents](#i0fdbfbedd57d460da77b9a8ab76925e1_7)\n\nPART I\n\nFINANCIAL INFORMATION"}